Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 May 3;4(5):e219807.
doi: 10.1001/jamanetworkopen.2021.9807.

Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis

Jun Du  1 , Dandan Yu  1 , Xinle Han  2 , Lijun Zhu  3 , Zoufang Huang  4
Affiliations
Meta-Analysis

Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis

Jun Du et al. JAMA Netw Open. .

Abstract

Importance: Hematopoietic stem cell transplant (HSCT) is an advisable option for refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), but whether allogeneic HSCT or autologous HSCT is more beneficial is unknown.

Objective: To compare the effectiveness and safety of allogeneic HSCT vs autologous HSCT in patients with R/R-PTCL.

Data sources: A systematic search of the PubMed, Embase, the Cochrane Central Register of Controlled Trials, Wanfang, and China National Knowledge Infrastructure databases with the search items refractory or relapsed peripheral T-cell lymphoma, ASCT/autologous stem-cell transplantation, allo-HSCT/allogeneic stem-cell transplantation, therapeutic effect, and treatment was conducted for articles published from January 12, 2001, to October 1, 2020.

Study selection: After duplicate and irrelevant publications were discarded, 329 were ineligible according to the inclusion (clinical trials or retrospective studies with >10 samples) and exclusion criteria (articles without overall survival [OS], progression-free survival [PFS], and transplantation-related mortality [TRM]). Thirty trials were included in the meta-analysis. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.

Data extraction and synthesis: Data on study design, individual characteristics, and outcomes were extracted. All statistics were pooled by applying a random-effects model.

Main outcomes and measures: The prespecified main outcomes were OS, PFS, and TRM.

Results: Of 6548 articles, data extracted from the 30 studies (including 880 patients who underwent allogeneic HSCT and 885 who underwent autologous HSCT) were included in this meta-analysis. In the allogeneic HSCT group, a 3-year OS of 50% (95% CI, 41%-60%) and PFS of 42% (95% CI, 35%-51%), a 5-year OS of 54% (95% CI, 47%-62%) and PFS of 48% (95% CI, 40%-56%), and a 3-year TRM of 32% (95% CI, 27%-37%) were observed. In the autologous HSCT group, a 3-year OS of 55% (95% CI, 48%-64%) and PFS of 41% (95% CI, 33%-51%), a 5-year OS of 53% (95% CI, 44%-64%) and PFS of 40% (95% CI, 24%-58%), and a 3-year TRM of 7% (95% CI, 2%-23%) were observed.

Conclusions and relevance: In this systematic review and meta-analysis, OS and PFS were similar in the allogeneic HSCT and autologous HSCT groups; however, allogeneic HSCT was associated with specific survival benefits among patients with R/R-PTCL.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Search Strategy
Figure 2.
Figure 2.. Three-Year Survival Outcomes in Patients with Refractory or Relapsed Peripheral T-Cell Lymphoma
HSCT indicates hematopoietic stem cell transplant; OS, overall survival; PFS, progression-free survival.
Figure 3.
Figure 3.. Five-Year Survival Outcomes in Patients with Refractory or Relapsed Peripheral T-Cell Lymphoma
HSCT indicates hematopoietic stem cell transplant; OS, overall survival; PFS, progression-free survival.
See this image and copyright information in PMC

Comment in

References

    1. Salhotra A, Nikolaenko L, Chen L, et al. Long term outcomes of patients with aggressive T-cell non-Hodgkin lymphoma undergoing allogeneic stem cell transplantation: retrospective results from single center. Biol Blood Marrow Transplant. 2020;26(3):S249. doi: 10.1016/j.bbmt.2019.12.499 - DOI
    1. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130. doi: 10.1200/JCO.2008.16.4558 - DOI - PubMed
    1. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970-1976. doi: 10.1200/JCO.2012.44.7524 - DOI - PubMed
    1. Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: peripheral T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99:214-227. doi: 10.1016/j.critrevonc.2015.12.016 - DOI - PubMed
    1. Domingo-Domènech E, Boumendil A, Climent F, et al. ; Lymphoma Working Party of the European Society for Blood and Marrow Transplantation . Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. a retrospective analysis of the lymphoma working party (LWP) of the EBMT. Bone Marrow Transplant. 2020;55(4):796-803. doi: 10.1038/s41409-019-0734-7 - DOI - PubMed

MeSH terms